Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
A Randomized Controlled Trial Comparing Three Sirolimus Discontinuation Strategies in Patients With Kaposiform Hemangioendothelioma
- Kaposiform Hemangioendothelioma
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- West China Hospital
- Enrolment target
- 120
- Started
- 13 September 2025
- Main results due
- 1 September 2027
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- No age limit is stated.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation. * With evaluable clinical or imaging parameters to monitor disease activity or recurrence. * Patients or their guardians are able to understand the study and provide written informed consent. * Hematologic and hepatic/renal function meet the safety criteria for drug administration. Exclusion Criteria: * Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.
What this study is about
In the sponsor’s own words, from the registry.
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Study sites(1)
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07131644. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me